Online Mindfulness-Based Intervention (eMBI) in management of dyspnea in patients with interstitial lung disease: A randomized clinical trial.
Siliana Maria Duarte Miranda, Sara de Pinho Cunha Paiva, Luiz Fernando Ferreira Pereira, Gabriela Patrus Ananias De Assis Pires, Andrew Nogueira Albuquerque Leal, Giane Amorim Ribeiro-Samora, Eliane Viana Mancuzo
Complementary therapies in medicine December 1, 2024 DOI: 10.1016/j.ctim.2024.103106 via PubMed
Summary
AI-generated from the abstractAn online mindfulness-based intervention (eMBI) over eight weeks helped reduce shortness of breath in patients with interstitial lung disease (ILD). In a controlled trial, 48.9% of those who completed the eMBI reported less dyspnea on the mMRC scale, compared with 15.4% in the control group. The program did not significantly improve cough-related quality of life, overall quality of life, depression, anxiety, or stress. No moderate or severe side effects occurred. The approach appears safe and potentially useful for managing breathlessness in ILD.
Study at a glance
| Characteristics | Prospective, open-label, controlled trial Randomized Peer reviewed |
|---|---|
| Sample size | 49 |
| Population | Adults with interstitial lung disease and mMRC dyspnea score ≥ 1 |
| Intervention | Online Mindfulness-Based Intervention (eMBI) |
| Duration | 8-week intervention |
| Topics | Meditation |
| Keywords | Pulmonary fibrosis Quality of life |
| Citations | 3 |
| Key finding | A greater proportion of patients who completed an eight-week online mindfulness-based intervention showed reduced dyspnea compared with the control group (48.9% vs. 15.4%). |
Abstract
Dyspnea and cough are frequent symptoms in ILD patients. The management of these symptoms is challenging, and evidence-based therapies are lacking. To evaluate the effect of an online Mindfulness-Based Intervention (eMBI) on reducing dyspnea in patients affected by different ILDs. This study was a prospective, open-label, controlled trial that included patients ≥18 years and a modified Medical Research Council (mMRC) dyspnea scale score of ≥ 1. Patients were randomized into either the eMBI or the control group (CG) for 8 weeks. The primary outcome was the change in the dyspnea mMRC scale. The Leicester Cough Questionnaire (LCQ), King's Brief Interstitial Lung Disease (K-BILD) questionnaire, and Depression, Anxiety, and Stress Scale (DASS-21) were performed before and after the eight weeks. All analyses were conducted on an intention-to-treat basis. The study was registered at the Brazilian Registry of Clinical Trials (ReBEC), RBR-3s4mf9y. 24 patients in the eMBI and 25 in the CG completed the intervention. In the eMBI group, compared to the control group, there was a greater proportion of patients with a reduction in dyspnea according to the mMRC scale score (48.9 % versus, 15.4 %, p = 0.001). There was no significant difference between the groups in the LCQ (p = 0.666), or in the K-BILD (p = 0.108), depression (p = 0.08), or anxiety (p = 0.869 or stress (p = 0.789). No moderate or severe adverse events were observed in either group. Eight weeks eMBI is a potentially viable and safe approach, that can help manage dyspnea in ILD patients.